A Mini Review on Effect of Corona Virus on Cancer Related to Lungs
Authors: Chauhan Ujjwal , Kumar Nitesh , Chopra Arshdeep , Sharma Yash , Singh Ajay Pal , Sharma P.K. , Mahima  
Published: December 2024

Abstract:
The emergence of the COVID-19 pandemic, caused by the SARS-CoV-2 virus, has significantly
impacted cancer patients, particularly those with lung cancer. This review delves into the
intersection of COVID-19 and lung cancer, addressing concerns regarding diagnosis, treatment, and
outcomes. Research demonstrates that patient co-factors, including age, sex, blood type, and
knowledge levels, are strongly associated with the severity and mortality of COVID-19 in lung
cancer patients. Older age, male gender, and specific blood types correlate with worse results. Cancer
patients, already immunocompromised, face heightened risks from COVID-19, with increased morbidity
and mortality rates. The pandemic has necessitated rapid adjustments in oncological care, including
telemedicine and altered treatment protocols. Vaccination tactics are essential, with
effectiveness differing based on whether patients have gotten the initial dosage, second dose, or
booster doses. Various vaccination forms, including mRNA vaccines, viral vector vaccines, and
inactivated virus vaccines, have differing effectiveness profiles, particularly in immunocompromised
persons. Booster dosages have shown improved immunity against developing variations such as
Delta and Omicron. Lung cancer, the second most diagnosed cancer globally, presents diverse challenges
due to its association with smoking and exposure to environmental carcinogens. Diagnosis
relies on histological confirmation, with treatment decisions guided by disease staging and molecular
profiling. Innovative diagnostic tools, such as molecular markers and genetic sequencing, enhance
personalized treatment approaches. The pandemic's impact on cancer diagnosis and treatment pathways
underscores the need for vigilant surveillance and adaptive strategies to ensure optimal patient
care. This abstract encapsulates the critical considerations and evolving landscape of managing
COVID-19 and lung cancer, emphasizing the importance of tailored approaches in navigating these
intertwined health crises. The abstract summarizes the diagnostic and management approaches for
lung cancer and COVID-19, highlighting key methods such as radiographic screening, liquid biopsy,
sputum examination, and nucleic acid amplification tests for diagnosis. Treatment strategies for both
conditions are discussed, emphasizing the challenges faced by lung cancer patients, particularly in
the context of COVID-19 infections. The abstract also addresses the importance of early detection
through biomarker discovery and the development of new therapies tailored to individual patients.
Furthermore, prognostic and predictive biomarkers for lung cancer are identified, such as EGFR
mutations and ALK rearrangements, which inform treatment decisions. The abstract underscores the
need for comprehensive care strategies that consider the intersection of lung cancer and COVID-19,
ensuring optimal outcomes for affected patients. Ultimately, care strategies must take consideration
of patient co-factors like age, sex, blood group, and knowledge levels, as well as vaccine
administration schedules like first doses, second doses, and booster shots and vaccine type
reflections. The overall strategy aims to improve treatment and immunization efficacy, improving
lung cancer outcomes during the COVID-19 pandemic.